الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 138 |  |  |
| | | from | 138 | | |
Abstract
OBJECTIVES: to test the hypothesis that 17P given to mothers with PROM before 32 weeks of gestation will prolong the pregnancy and thereby reduce neonatal morbidity.
METHODS: This study included 112 pregnant women admitted to Ain shams university hospital to assess the efficacy of intramuscular progesterone compared to placebo therapy in decreasing the rate of preterm birth in women with PPROM pregnancy, selected on basis being with age between 18-35 years, carrying Singleton pregnancy, at gestational age between24-34 weeks. The pregnant women were randomly arranged by closed envelop method according to randomization table into two groups, (placebo group and intramuscular progesterone group), 56women in case (control) group & 56 women in (intramuscular progesterone) group. All patients were followed up until delivery. The primary outcome measure is prolongation of the pregnancy until 34.0 weeks of gestation or documentation of fetal lung maturity at 32.0 to 33.9 weeks.
RESULTS: RDS, NICU admission and neonatal death were statistically non-significant but less frequent among intramuscular group. The present study provides no evidence that 17OHP-C is beneficial in women with PROM.
CONCLUSION: Weekly intramuscular 17-hydroxyprogesterone caproate does not prolong the latency in PPROM versus placebo